Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM4 | P08173 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
| ▸ | KCNJ1 | P48048 | 1/20 | 0.31 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28840799 | 0.84 | PRMT5 (0.38) | — | |
| SCHEMBL12240635 | 0.78 | TRPA1 (0.40) | CHRM4KDM4EMAPTL3MBTL1 | |
| SCHEMBL1466786 | 0.78 | CA12 (0.35) | KCNJ1KCNH2 | |
| SCHEMBL7699218 | 0.78 | HRH3 (0.37) | — | |
| SCHEMBL30523718 | 0.78 | HRH3 (0.37) | — | |
| SCHEMBL1467009 | 0.78 | TRPA1 (0.32) | CHRM4KDM4EMAPTL3MBTL1KCNJ1 | |
| SCHEMBL29356674 | 0.78 | CA12 (0.35) | KCNJ1KCNH2 | |
| Hydrochloric Acid SCHEMBL31165140 | 0.77 | RAD52 (0.39) | — | |
| SCHEMBL1466332 | 0.76 | RXRB (0.42) | MAPT | |
| SCHEMBL19812842 | 0.75 | KDM4E (0.45) | KDM4EMAPTKCNJ1KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116583286-A | Tetrahydrothienopyrimidine sulfonamide compounds | 某久拉斯株式会社 | 2023-08-11 | — | — | CN | disclosed |
| US-20230104936-A1 | TRPML MODULATORS | CASMA THERAPEUTICS, INC. | 2023-04-06 | — | — | US | disclosed |
| EP-4076423-A1 | TRPML MODULATORS | Casma Therapeutics, Inc. (US) | 2022-10-26 | — | — | EP | disclosed |
| CN-115087440-A | TRPML modulators | 卡斯玛治疗公司 | 2022-09-20 | — | — | CN | disclosed |
| CN-114907389-A | Boronic acid derivatives | 首药控股(北京)股份有限公司 | 2022-08-16 | — | — | CN | disclosed |
| WO-2022138812-A1 | TETRAHYDRO THIENOPYRIDINE SULFONAMIDE COMPOUND | モジュラス株式会社 | 2022-06-30 | — | — | WO | disclosed |
| WO-2021127337-A1 | TRPML MODULATORS | CASMA THERAPEUTICS, INC. (US) | 2021-06-24 | — | — | WO | disclosed |
| WO-2021127337-A1 | TRPML MODULATORS | CASMA THERAPEUTICS, INC. (US) | 2021-06-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230104936-A1 | TRPML MODULATORS | TRPM2, TRPM4, TRPM5 | CHRM4 86/4885KDM4E 2480/4885MAPT 1167/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.